Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 09 Dec 2017 Primary endpoint (Objective Response Rate) has not been met, as per results presented at the 40th Annual San Antonio Breast Cancer Symposium.
- 09 Dec 2017 Results assessing efficacy and safety, presented at the 40th Annual San Antonio Breast Cancer Symposium.
- 25 Nov 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.